Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409262 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 649
- Enrollment target
NCT04409262 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 649 participants.
The verdict
NCT04409262, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 649 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
Interventions
- DRUG Placebo
- DRUG Tocilizumab
- DRUG Remdesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 649 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409262
The ClinicalTrials.gov registry entry for NCT04409262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 649 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04409262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04409262 about?
NCT04409262 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia". This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
What is the current status of trial NCT04409262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 649 participants. The study started on 2020-06-16. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT04409262?
The interventions under investigation include: Placebo (DRUG), Tocilizumab (DRUG), Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04409262?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.